Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 14
2003 13
2004 10
2005 25
2006 7
2007 15
2008 21
2009 24
2010 36
2011 27
2012 44
2013 45
2014 48
2015 58
2016 45
2017 38
2018 57
2019 53
2020 38
2021 77
2022 74
2023 62
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

721 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for ae yong kim
Search for Ae Young Kim instead (2 results)
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Sakata J, Yonemori K, Kim YM, Guerra EM, Sanli UA, McCormack MM, Smith AD, Keefe S, Bird S, Dutta L, Orlowski RJ, Lorusso D; Study 309–KEYNOTE-775 Investigators. Makker V, et al. Among authors: kim ym. N Engl J Med. 2022 Feb 3;386(5):437-448. doi: 10.1056/NEJMoa2108330. Epub 2022 Jan 19. N Engl J Med. 2022. PMID: 35045221 Clinical Trial.
The median overall survival was longer with lenvatinib plus pembrolizumab than with chemotherapy (pMMR population: 17.4 vs. 12.0 months; hazard ratio for death, 0.68; 95% CI, 0.56 to 0.84; P<0.001; overall: 18.3 vs. 11.4 months; hazard ratio, 0.62; 95% CI, 0.51 to 0.75; P<0 …
The median overall survival was longer with lenvatinib plus pembrolizumab than with chemotherapy (pMMR population: 17.4 vs. 12.0 months; haz …
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzén F, Noh SH; CLASSIC trial investigators. Bang YJ, et al. Among authors: kim yh. Lancet. 2012 Jan 28;379(9813):315-21. doi: 10.1016/S0140-6736(11)61873-4. Epub 2012 Jan 7. Lancet. 2012. PMID: 22226517 Clinical Trial.
Median follow-up was 34.2 months (25.4-41.7) in the chemotherapy and surgery group and 34.3 months (25.6-41.9) in the surgery only group. 3 year disease-free survival was 74% (95% CI 69-79) in the chemotherapy and surgery group and 59% (53-64) in the surgery only group (hazard ra …
Median follow-up was 34.2 months (25.4-41.7) in the chemotherapy and surgery group and 34.3 months (25.6-41.9) in the surgery only group. 3 …
Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology-RTOG 1203.
Klopp AH, Yeung AR, Deshmukh S, Gil KM, Wenzel L, Westin SN, Gifford K, Gaffney DK, Small W Jr, Thompson S, Doncals DE, Cantuaria GHC, Yaremko BP, Chang A, Kundapur V, Mohan DS, Haas ML, Kim YB, Ferguson CL, Pugh SL, Kachnic LA, Bruner DW. Klopp AH, et al. Among authors: kim yb. J Clin Oncol. 2018 Aug 20;36(24):2538-2544. doi: 10.1200/JCO.2017.77.4273. Epub 2018 Jul 10. J Clin Oncol. 2018. PMID: 29989857 Free PMC article. Clinical Trial.
Secondary end points included change in patient-reported urinary toxicity, change in GI toxicity measured with the Patient-Reported Outcome Common Terminology Criteria for Adverse Events, and quality of life measured with the Trial Outcome Index. ...
Secondary end points included change in patient-reported urinary toxicity, change in GI toxicity measured with the Patient-Reported Outcome …
Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial.
Kim BK, Hong SJ, Cho YH, Yun KH, Kim YH, Suh Y, Cho JY, Her AY, Cho S, Jeon DW, Yoo SY, Cho DK, Hong BK, Kwon H, Ahn CM, Shin DH, Nam CM, Kim JS, Ko YG, Choi D, Hong MK, Jang Y; TICO Investigators. Kim BK, et al. Among authors: kim yh. JAMA. 2020 Jun 16;323(23):2407-2416. doi: 10.1001/jama.2020.7580. JAMA. 2020. PMID: 32543684 Free PMC article. Clinical Trial.
OBJECTIVE: To determine whether switching to ticagrelor monotherapy after 3 months of DAPT reduces net adverse clinical events compared with ticagrelor-based 12-month DAPT in patients with ACS treated with drug-eluting stents. ...MAIN OUTCOMES AND MEASURES: The primary out …
OBJECTIVE: To determine whether switching to ticagrelor monotherapy after 3 months of DAPT reduces net adverse clinical events compar …
Advances in Pituitary Surgery.
Byun YH, Kang H, Kim YH. Byun YH, et al. Among authors: kim yh. Endocrinol Metab (Seoul). 2022 Aug;37(4):608-616. doi: 10.3803/EnM.2022.1546. Epub 2022 Aug 19. Endocrinol Metab (Seoul). 2022. PMID: 35982611 Free PMC article. Review.
Exogenous influences on intraocular pressure.
Kim YW, Park KH. Kim YW, et al. Br J Ophthalmol. 2019 Sep;103(9):1209-1216. doi: 10.1136/bjophthalmol-2018-313381. Epub 2019 Mar 25. Br J Ophthalmol. 2019. PMID: 30910873 Review.
Efficacy and safety of enavogliflozin versus dapagliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: A double-blind, randomized, comparator-active study: ENHANCE-D study.
Kim KS, Han KA, Kim TN, Park CY, Park JH, Kim SY, Kim YH, Song KH, Kang ES, Kim CS, Koh G, Kang JG, Kim MK, Han JM, Kim NH, Mok JO, Lee JH, Lim S, Kim SS, Kim TH, Won KC, Lee KY, Cho JH, Han JY, Kim SH, Nah JJ, Song HR, Lee SE, Kim S; ENHANCE-D Investigators. Kim KS, et al. Among authors: kim yh. Diabetes Metab. 2023 Jul;49(4):101440. doi: 10.1016/j.diabet.2023.101440. Epub 2023 Mar 9. Diabetes Metab. 2023. PMID: 36906135 Free article. Clinical Trial.

An increase in urine glucose-creatinine ratio was significantly greater in the enavogliflozin group than in the dapagliflozin group (60.2 g/g versus 43.5 g/g, P < 0.0001). The incidence of treatment-emergent adverse events was similar between the groups (21.64% versus 2

…
An increase in urine glucose-creatinine ratio was significantly greater in the enavogliflozin group than in the dapagliflozin group (60.2 g/ …
Neuro-Ophthalmic Adverse Events of COVID-19 Infection and Vaccines: A Nationwide Cohort Study.
Han JY, Kim S, Han J, Kim SS, Han SH, Lee SW, Kim YJ. Han JY, et al. Among authors: kim yj. Invest Ophthalmol Vis Sci. 2023 Nov 1;64(14):37. doi: 10.1167/iovs.64.14.37. Invest Ophthalmol Vis Sci. 2023. PMID: 38010696 Free PMC article.
RESULTS: Neuro-ophthalmic adverse events other than ptosis and GBS/MFS exhibited no significant increase after COVID-19, and their incidence was extremely low. ...In contrast, no association was found between other neuro-ophthalmic adverse events and COVID-19 infect …
RESULTS: Neuro-ophthalmic adverse events other than ptosis and GBS/MFS exhibited no significant increase after COVID-19, and their in …
721 results